


PHARMACEUTICAL 2017

ENDOCYTE INC Rank 19 of 292







PHARMACEUTICAL 2017



ENDOCYTE INC Rank 19 of 292

The relative strengths and weaknesses of ENDOCYTE INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDOCYTE INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of ENDOCYTE INC is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 256%, being 253% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	140,256
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,562
Liabilities, Non-Current	2.9
Other Assets	34
Other Compr. Net Income	38
Other Expenses	0
Other Liabilities	782
Other Net Income	903
Other Revenues	0
Property and Equipment	3,205
Research and Development	27,492
Selling, General and Administrative Expense	17,298

Output Variable	Value in 1000 USD
Assets	143,494
Liabilities	6,347
Expenses	44,790
Revenues	0
Stockholders Equity	137,147
Net Income	-43,888
Comprehensive Net Income	-43,868
Economic Capital Ratio	256%

